Overview

QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC

Status:
Recruiting

Trial end date:
2025-09-30

Target enrollment:

Participant gender:

Summary

This is an open-label, muticenter phase II study to evaluate the efficacy and safety of QL1706 monotherapy or in combination with bevacizumab and XELOX as first-line treatment of unresectable advanced or metastatic CRC.

Phase:

Phase 2

Details

Lead Sponsor:

Qilu Pharmaceutical Co., Ltd.

Treatments:

Bevacizumab
Capecitabine
Oxaliplatin